No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Jan 9, 2026
On 9 January 2026, Aurobindo Pharma announced in a regulatory filing that its subsidiary, CuraTeQ Biologics, has received approval from Health Canada for Dyrupeg®, biosimilar to Amgen’s Neulasta® (pegfilgrastim). In the same regulatory filing, CuraTeq also disclosed that it has three other biosimilar applications currently under review with Health Canada.
Jan 9, 2026
On 9 January 2026, Boan Biotech announced that it has received regulatory approval from Bolivia’s National Agency of Medicines and Health Technologies (AGEMED) for BA6101, its 60 mg denosumab injection, biosimilar to Amgen’s Prolia®. BA6101 is approved for the same indications as the reference product.
Jan 8, 2026
On 8 January 2026, Takeda announced that it has entered a global collaboration and licence agreement with Halozyme Therapeutics, Inc, which grants Takeda exclusive rights to Halozyme’s Enhanze® drug delivery technology for use with Takeda’s Entyvio® (vedolizumab).
Jan 8, 2026
On 8 January 2026, the Munich Regional Court granted Regeneron and Bayer a preliminary injunction (PI) preventing STADA, Hexal, Celltrion and Advanz Pharma from marketing their aflibercept biosimilars in Germany and requiring them to recall any products already on the market.
Jan 7, 2026
GSK’s Nucala® (mepolizumab) has received approval in China and the UK as an add-on maintenance treatment for adult patients with inadequately controlled COPD characterised by raised blood eosinophils.
Jan 6, 2026
On 6 January 2026, Fresenius Kabi announced that it has introduced a new presentation of Otulfi®, biosimilar to Janssen’s/J&J’s Stelara® (ustekinumab), in a 45 mg/0.5 mL single-dose vial for subcutaneous injection.
Jan 6, 2026
On 6 January 2026, Biocon Biologics announced that it will unveil three new biosimilars at the 2026 J.P. Morgan Healthcare Conference to be held 12-16 January 2026 in San Francisco.
Jan 2, 2026
On 2 January 2026, Samsung Bioepis announced that it has begun direct commercialisation of Byooviz®, biosimilar to Genentech’s Lucentis® (ranibizumab), in Europe, following the transfer back of commercial rights from Biogen to Samsung Bioepis.
Jan 1, 2026
On 1 January 2026, Medical Dialogues reported that Dr Reddy’s has disclosed to various stock exchanges that it has received a Complete Response Letter (CRL) from the FDA in relation to its Biologics Licence Application (BLA) for AVT03, biosimilar to Amgen’s Prolia® and Xgeva® (denosumab).
Dec 31, 2025
On 31 December 2025, Outlook Therapeutics announced that the FDA issued a Complete Response Letter (CRL) regarding the second resubmission of its Biologics Licence Application (BLA) for its ophthalmic formulation of bevacizumab, ONS-5010/Lytenava™, for wet AMD.
Dec 31, 2025
On 31 December 2025, Mabwell announced that it has received marketing approval from the Indonesian Food and Drug Authority for its Adalimumab Injection 9MW0113, biosimilar to AbbVie’s Humira®.
Dec 27, 2025
On 27 December 2025, Medical Dialogues reported that Aurobindo Pharma’s wholly-owned subsidiary, CuraTeQ, had terminated its agreement with US-based BioFactura Inc regarding BFI-751, biosimilar to Janssen’s/J&J’s Stelara® (ustekinumab).
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.